Investing.com··Chris MarkochGene-Editing Pioneers Emerge as M&A Targets Amid $300B Biotech Patent Cliff
Biotech M&A surges as $300B patent cliff looms by 2030. Three gene-editing firms positioned as acquisition targets offer varying risk profiles.
BMYCELGrMRKBEAMCRSP+1patent cliffCRISPR